JPM26: Integra restarts by fixing supply and taking advantage of tailwinds in reimbursement

Integra LifeSciences used its update at the ongoing 2026 JP Morgan Healthcare Conference in San Francisco to frame 2025 and 2026 as a deliberate transition period. The company described a shift from disruption and remediation toward more predictable execution, supported by product relaunches, a more resilient supply chain and reimbursement changes that could make parts of its wound portfolio more financially attractive in outpatient settings.

Integra dedicated an important part of the presentation to its “two horizons” plan. As presented, Horizon 1 is about rebuilding a sustainable foundation through quality systems, supply chain reliability and improved working capital discipline. Management emphasized that demand in 2025 exceeded what it could deliver, and that better manufacturing planning and consistency is expected to translate into better service levels and greater capacity to meet demand, along with stronger cash flow and improved profitability over time.

Horizon 2 is intended to deliver faster growth through the generation of clinical evidence, new indications for existing tissue technologies, and investment in neurosurgery and otolaryngology, enabled by a 2025 portfolio prioritization exercise that management says helps direct capital toward higher-growth, higher-margin areas. The company positioned these workflows as moving forward simultaneously, with fundamental improvements aimed at making growth initiatives more repeatable and scalable.

The practical test of this reset is whether Integra can restore availability to product lines that have faced recalls or extended exits from the market. Multiple products have been affected by quality and remediation issues, which has limited supply. Integra noted that it relaunched PriMatrix and Durepair in Q4 2025, and highlighted SurgiMend as a planned launch for Q4 2026. GlobalData’s SKU analysis suggests early traction from this relaunch, with PriMatrix sales at US healthcare institutions increasing by more than 80% between 2024 and 2025.

To further support these efforts, the company discussed supply resiliency initiatives, including a new manufacturing facility in Braintree, Massachusetts, expected to be operational in the first half of 2026. Looking at the recalls and relaunch priorities disclosed to date, tissue-based wound and reconstruction products appear to be at the center of both the recent disruption and planned recovery, making execution on this franchise critical to regaining momentum.

Tissue technologies are an important part of Integra’s revenue mix and investor narrative, and the Tissue Engineered Skin Substitutes (TESS) segment is one of the fastest growing areas within it. GlobalData estimates that the TESS market will grow from $2.6 billion in 2025 to $3.9 billion in 2030, implying a compound annual growth rate of 8.6%.

Within this market, GlobalData estimates that Allergan, part of AbbVie, leads with a 24% share, followed by Integra with 16% and Organogenesis with 14%. This presents a substantial market opportunity, but Integra is only likely to capitalize on it if it can maintain stable manufacturing and generate credible clinical evidence as utilization grows with an aging population and broader demand for reconstruction and chronic wounds.

In its presentation, Integra also noted the Centers for Medicare and Medicare Services (CMS) reimbursement changes for skin substitutes that went into effect on January 1, 2026. These changes shift most products to a standardized payment of approximately $127.3 per square centimeter across all sites of care. Integra argued that its price is in line with the new tariff, making the products not only clinically attractive but also easier to justify economically, without implying margin compression.

In otolaryngology, the company noted that the first year after the Acclarent acquisition met expectations, while balloon sinuplasty faced unanticipated declines in 2025 tied to reimbursement dynamics. GlobalData’s estimates underscore Integra’s scale in that category, with Acclarent accounting for estimated revenue of $518 million in 2025, more than 70% share of the $810 million balloon sinuplasty market. If reimbursement issues ease, that concentration could quickly change the segment’s performance.

Integra’s story in early 2026 is less about a single breakthrough and more about earning the right to grow again. Management said it is targeting modest growth in 2026 and is working to achieve organic growth at least in line with the markets it serves. For that to be realistic, the key levers are likely simple: consistent product supply, clean execution on relaunches, and sustained clinical and economic relevance in fast-growing wound categories.

Sign up here to receive daily updates on the latest healthcare industry trends emerging from the JP Morgan Healthcare Conference 2026. Sign up here to receive a full report after the conference.

“JPM26: Integra Reboots by Fixing Supply and Taking Advantage of Reimbursement Tailwinds” was created and originally published by Medical Device Network, a brand owned by GlobalData.

The information contained on this site has been included in good faith for general information purposes only. It is not intended to be advice on which you should rely, and we make no representation or warranty, whether express or implied, as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action based on the content on our site.